OncologyPancreatic Neoplasms

Cracking the Undruggable: KRAS Inhibitors Rewrite Solid Tumor Oncology

From G12C to pan-RAS: the mutation-by-mutation guide to the KRAS revolution

Published 14 July 2026SR-2026-002

EditorMara Voss

CopywritersEditorial Team

Coming Soon

Cracking the Undruggable: KRAS Inhibitors Rewrite Solid Tumor Oncology

From G12C to pan-RAS: the mutation-by-mutation guide to the KRAS revolution

Why We Are Covering This

KRAS was considered undruggable for four decades. The RASolute-302 data at ASCO 2026 nearly doubled overall survival in pancreatic cancer, making this the most consequential solid tumor dataset of the year.

What to Expect

You will understand the clinical differences between G12C, G12D, and pan-RAS inhibition, which tumor types benefit most, and how resistance mechanisms are shaping next-generation combination strategies.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first

thelifesciencefeed.com · Special Report

SR-2026-00207/26

Solid Tumors

Bowhead Whale Longevity Genes Offer Clues for Cancer, Aging

Insights from the bowhead whale's exceptional lifespan and cancer resistance point to novel genetic pathways for human anti-aging and oncology research.

Prostatic Neoplasms

Prostate Care: Balancing Immediate Relief with Long-Term Retreatment

Managing benign prostatic hyperplasia requires weighing rapid symptom improvement against the need for future interventions. Clinicians must consider patient preference and disease progression.

Breast Neoplasms

Genetic Test Identifies Breast Cancer Patients Who May Avoid Chemotherapy

A genetic test can identify patients with early-stage, hormone receptor-positive, HER2-negative breast cancer who may safely forgo adjuvant chemotherapy.

Breast Neoplasms

Giredestrant Improves Breast Cancer Survival Regardless of Menopause

Giredestrant, an oral selective estrogen receptor degrader (SERD), demonstrated improved invasive disease-free survival in early breast cancer.

Cracking the Undruggable: KRAS Inhibitors Rewrite Solid Tumor Oncology

Cracking the Undruggable: KRAS Inhibitors Rewrite Solid Tumor Oncology

Be first when this report publishes

Related Articles